# Ketamine Combined With Psychotherapy as a Treatment for Resistant Depression in a Public European Hospital

**Authors:** Filipa Alves da Silva, Rita Avelar, Bernardo Peixoto, Leonor Bacelar‐Nicolau, Francisco Santos, João Costa Ribeiro, Maria João Heitor

PMC · DOI: 10.1002/brb3.71164 · Brain and Behavior · 2026-01-13

## TL;DR

A pilot study found that combining ketamine infusions with psychotherapy improved symptoms in patients with treatment-resistant depression.

## Contribution

This is one of the first studies to evaluate ketamine plus psychotherapy in a public hospital setting for treatment-resistant depression.

## Key findings

- All nine patients showed reduced PHQ-9 scores from severe to moderate depression after eight weeks.
- 44% of participants had a ≥50% reduction in PHQ-9 scores, indicating treatment response.
- Over half of patients with suicidal thoughts experienced remission after treatment.

## Abstract

Depression affects around 280 million people worldwide, and about 30% of patients have treatment‐resistant depression. Ketamine has significant scientific evidence supporting its use as an antidepressant, making it a promising approach for treatment‐resistant cases. Combining ketamine with psychotherapy may enhance therapeutic response and support longer‐lasting cognitive and behavioral change. This pilot proof‐of‐concept study aims to evaluate the effect of treatment with ketamine infusion combined with psychological intervention in a sample of nine patients with treatment‐resistant depression at a general hospital within the Portuguese National Health Service.

Clinical outcomes were measured through the clinical interview and the patient health questionnaire (PHQ‐9) to assess complete or partial improvement.

Following eight weeks of treatment, all showed a reduction in their PHQ‐9 scores, with the median score transitioning from a baseline categorization of “severe” depression to a “moderate” level. It was found that 44.4% (4/9) of participants showed a response to treatment (≥ 50% reduction in the PHQ‐9 score). Among the patients with suicidal ideation, slightly over half showed remission of these thoughts at the end of treatment. Among the participants subsequently monitored as outpatients, only 29% (2/7) experienced a deterioration in mood within three months post‐treatment, requiring an adjustment of antidepressant therapy.

In our study, an improvement in depressive symptoms was observed, despite their severity, in a sample submitted to multiple previous pharmacological strategies.This retrospective study evaluated ketamine infusions combined with psychotherapy in nine patients with treatment‐resistant depression at a general hospital. After eight weeks, all participants improved, with PHQ‐9 scores shifting from severe to moderate. Overall, 44% responded to treatment, and among those with suicidal ideation, more than half showed remission.

This retrospective study evaluated ketamine infusions combined with psychotherapy in nine patients with treatment‐resistant depression at a general hospital. After eight weeks, all participants improved, with PHQ‐9 scores shifting from severe to moderate. Overall, 44% responded to treatment, and among those with suicidal ideation, more than half showed remission.

## Linked entities

- **Chemicals:** ketamine (PubChem CID 3821)
- **Diseases:** depression (MONDO:0002050)

## Full-text entities

- **Genes:** BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}
- **Diseases:** COVID-19 (MESH:D000086382), Depression (MESH:D003866), obsessive-compulsive disorder (MESH:D009771), headache (MESH:D006261), urological toxicity (MESH:D014570), dizziness (MESH:D004244), psychotic symptoms (MESH:D011618), anxiety disorder (MESH:D001008), bipolar depression (MESH:D001714), death (MESH:D003643), opioid use disorder (MESH:D009293), suicidal ideation (MESH:D001072), allergy (MESH:D004342), SCID (MESH:D053632), anxiety (MESH:D001007), urinary or renal complications (MESH:D007674), blurred vision (MESH:D014786), eating disorders (MESH:D001068), elevated blood pressure (MESH:D006973), psychiatric (MESH:D001523), post-traumatic stress disorder (MESH:D013313), psychomotor inhibition (MESH:C565433), drug abuse (MESH:D019966), analgesia (MESH:D000699), TRD (MESH:D061218), social phobia (MESH:D000072861)
- **Chemicals:** oxygen (MESH:D010100), alcohol (MESH:D000438), quetiapine (MESH:D000069348), Esketamine (MESH:C000629870), cocaine (MESH:D003042), Ketamine (MESH:D007649), naltrexone (MESH:D009271), Ketamine Infusion (-), Li (MESH:D008094), psilocybin (MESH:D011562), LSD (MESH:D008238)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12796847/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12796847/full.md

## References

68 references — full list in the complete paper: https://tomesphere.com/paper/PMC12796847/full.md

---
Source: https://tomesphere.com/paper/PMC12796847